KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) EBITDA: 2009-2024

Historic EBITDA for Alnylam Pharmaceuticals (ALNY) over the last 15 years, with Dec 2024 value amounting to -$289.3 million.

  • Alnylam Pharmaceuticals' EBITDA rose 354.78% to $259.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $46.6 million, marking a year-over-year increase of 114.35%. This contributed to the annual value of -$289.3 million for FY2024, which is 30.95% up from last year.
  • As of FY2024, Alnylam Pharmaceuticals' EBITDA stood at -$289.3 million, which was up 30.95% from -$419.0 million recorded in FY2023.
  • Alnylam Pharmaceuticals' EBITDA's 5-year high stood at -$289.3 million during FY2024, with a 5-year trough of -$1.1 billion in FY2022.
  • For the 3-year period, Alnylam Pharmaceuticals' EBITDA averaged around -$616.9 million, with its median value being -$419.0 million (2023).
  • In the last 5 years, Alnylam Pharmaceuticals' EBITDA crashed by 35.62% in 2022 and then surged by 63.33% in 2023.
  • Over the past 5 years, Alnylam Pharmaceuticals' EBITDA (Yearly) stood at -$865.4 million in 2020, then grew by 2.65% to -$842.5 million in 2021, then slumped by 35.62% to -$1.1 billion in 2022, then soared by 63.33% to -$419.0 million in 2023, then surged by 30.95% to -$289.3 million in 2024.